Fenebrutinib
-
Fenebrutinib: First New Treatment in Over a Decade to Combat Progressive MS Disability
Roche’s investigational drug, fenebrutinib, shows promise in slowing disability progression for primary progressive multiple sclerosis (PPMS). As a BTK inhibitor, it targets inflammation in the central nervous system. This potential breakthrough offers hope for PPMS patients, who have had limited treatment options. The success of fenebrutinib could also validate BTK inhibitors for other neurological conditions, driving further research and investment.